Literature DB >> 10466471

Effect of insulin resistance on left ventricular hypertrophy and dysfunction in essential hypertension.

K Watanabe1, M Sekiya, T Tsuruoka, J Funada, H Kameoka.   

Abstract

BACKGROUND: In hypertensive patients, the relationships between glucose tolerance and left ventricular hypertrophy (LVH) and left ventricular diastolic function (LVDF) have been described in several reports.
OBJECTIVE: In this study, we examined the relationships between insulin resistance and LVH and LVDF in hypertensive patients from the therapeutic perspective. METHODS AND
RESULTS: The study participants were essential hypertensive patients with impaired glucose tolerance (IGT-HT, n = 26), hypertensive patients with normal glucose tolerance (NGT-HT, n = 39), and normotensive control individuals (n = 18). Insulin resistance was evaluated by the insulin suppression test by use of the steady-state plasma glucose (SSPG) level. Left ventricular mass index (LVMI) and LVDF, which was determined by the E:A ratio, were estimated by echocardiography. Temocapril, an angiotensin-converting enzyme inhibitor, was administered in an open, non-randomized manner with a mean dose of 2.8+/-0.2 mg/ day, and the mean administration period was 18 weeks. The systolic and diastolic blood pressure, the LVMI, and the SSPG level were significantly higher in the hypertensive patients than in the control individuals. The mean systolic and diastolic blood pressures were significantly decreased by treatment with Temocapril. Before treatment, stepwise regression analysis showed that SSPG is an independent predictor for LVMI and LVDF. After treatment, the changes in LVMI (D-LVMI; %) (-15.1+/-1.5), the changes in LVDF (D-E:A; %) (-38.2+/-4.1), and the changes in insulin resistance (D-SSPG; %) (-13.7+/-1.7) were significantly higher in the IGT-HT group than in the NGT-HT group (-11.4+/-1.1, -18.1+/-1.7, -9.4+/-1.4, respectively), and the D-SSPG was an independent predictor for D-LVMI and D-E :A.
CONCLUSIONS: The results of this study indicate that insulin resistance is an important factor affecting LVH and LVDF.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10466471     DOI: 10.1097/00004872-199917080-00015

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  6 in total

1.  Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities study.

Authors:  Rachel R Huxley; Alvaro Alonso; Faye L Lopez; Kristian B Filion; Sunil K Agarwal; Laura R Loehr; Elsayed Z Soliman; James S Pankow; Elizabeth Selvin
Journal:  Heart       Date:  2011-09-19       Impact factor: 5.994

2.  Telmisartan improves myocardial remodeling by inhibiting leptin autocrine activity and activating PPARγ.

Authors:  Hui Chen; Min Li; Lei Liu; Danjun Zhu; Gang Tian
Journal:  Exp Biol Med (Maywood)       Date:  2020-02-19

3.  Determinants of left ventricular hypertrophy in hypertensive patients: identification of high-risk patients by metabolic, vascular, and inflammatory risk factors.

Authors:  Maya Peer; Mona Boaz; Matas Zipora; Marina Shargorodsky
Journal:  Int J Angiol       Date:  2013-12

4.  The possible role of peroxisome proliferator-activated receptor gamma in heart failure.

Authors:  Natsuhiko Ehara; Koh Ono; Tatsuya Morimoto; Teruhisa Kawamura; Mitsuru Abe; Koji Hasegawa
Journal:  Exp Clin Cardiol       Date:  2004

5.  Left ventricular mass index and subendocardial myocardial function in children with chronic kidney disease, a transmural strain and three-dimensional echocardiographic study.

Authors:  Amira Esmat El Tantawy; Fatina Fadel; Safaa M Abdelrahman; Marwa Nabhan; Reem Ibrahim; Aya M Fattouh; Shaimaa El Sayed; Khaled Mohamed ElKhashab; Peter Afdal; Antoine Fakhry AbdelMassih
Journal:  Cardiovasc Endocrinol Metab       Date:  2019-11-13

6.  Increased prevalence of left ventricular hypertrophy in hypertensive women with type 2 diabetes mellitus.

Authors:  Alexander Tenenbaum; Enrique Z Fisman; Ehud Schwammenthal; Yehuda Adler; Michal Benderly; Michael Motro; Joseph Shemesh
Journal:  Cardiovasc Diabetol       Date:  2003-11-23       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.